Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Xtandi (enzalutamide by Year
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — U.S. reported YoY (%) (%)
Pfizer Xtandi (enzalutamide: 8.0% in FY2025, down 15.0 pts from a year earlier.
Latest, FY2025
8.0%
Period ended Dec 31, 2025
Change on a year earlier
-15.0 pts
23.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Xtandi (f) | 2,194 | 2,039 | 8% | 8% | 2,194 | 2,039 | 8% | — | — | — | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Xtandi (enzalutamide (%), annual FY2018–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/xtandi-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.